Lessons From The Bone Therapeutics/Medsenic Merger With BioSenic's François Rieger, Ph.D.

We love to hear from our listeners. Send us a message. On the surface, the merger of Medsenic (a developer of arsenic salt formulations for therapeutic application in inflammatory conditions) and Bone Therapeutics (which develops allogeneic cell therapies for complicated bone fractures) doesn't look obviously synergistic. But Francois Rieger, Ph.D. says that on the scientific level, it's a perfect union, and the veteran biotech founder says the business should always follow the sc...